Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Huafeng Zhou

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Future Oncology (London, England)|April 29, 2024
A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancerYohann Loriot, Arash Rezazadeh Kalebasty, Aude Fléchon, et al.
The Lancet. Respiratory Medicine|April 11, 2014
Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trialGanesh Raghu, David Lynch, J David Godwin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2024
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3Petros Grivas, Damien Pouessel, Chandler H Park, et al.
The Lancet. Haematology|March 25, 2017
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trialRuben A Mesa, Alessandro M Vannucchi, Adam Mead, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Future Oncology (London, England)|April 29, 2024
A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancerYohann Loriot, Arash Rezazadeh Kalebasty, Aude Fléchon, et al.
The Lancet. Respiratory Medicine|April 11, 2014
Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trialGanesh Raghu, David Lynch, J David Godwin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2024
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3Petros Grivas, Damien Pouessel, Chandler H Park, et al.
The Lancet. Haematology|March 25, 2017
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trialRuben A Mesa, Alessandro M Vannucchi, Adam Mead, et al.
Pageof 3